Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
about
Review of renal cell carcinoma and its common subtypes in radiologyTherapeutic challenges in renal cell carcinomaMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesFrontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinomaTargeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapyIncidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysisIndividualising treatment choices in a crowded treatment algorithmProdrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor SunitinibLenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for responseHigh CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinomaDownregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation.A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer.Pazopanib-induced asymptomatic radiological acute pancreatitis: A case reportUncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialInsulin receptor expression in clear cell renal cell carcinoma and its relation to prognosis.Store-operated Ca2+ entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma.Clear cell changes in mucinous tubular and spindle cell carcinoma: cytoplasmic pallor/clearing within tubules, vacuoles or hybrid conventional clear cell carcinoma of kidney?Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma.Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinomaApproach via a small retroperitoneal anterior subcostal incision in the supine position for gasless laparoendoscopic single-port radical nephrectomy: initial experience of 42 patients.Apparent diffusion coefficient measurement by diffusion weighted magnetic resonance imaging is a useful tool in differentiating renal tumors.Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.Pazopanib-induced alopecia, an underestimated toxicity?Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of β-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell CarcinomaSunitinib re-challenge in advanced renal-cell carcinoma.MRI phenotype in renal cancer: is it clinically relevant?Tumor size, stage and grade alterations of urinary peptidome in RCC.Synchronous quadruple multiple primary cancers of the tongue, bilateral breasts, and kidney in a female patient with a disease-free survival time of more than 5 years: a case report.Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.The discovery and development of sorafenib for the treatment of thyroid cancer.
P2860
Q26744297-3705501B-96F2-4C07-854F-527890355831Q26796702-19F6813E-AED4-404F-9799-EB16A67A7552Q26852437-8725149C-A235-4A57-9D34-05377227C073Q26863402-8C3AC070-6200-4CC9-8889-E5B6D4835C69Q26991589-75B2335F-C4D4-4464-AF7B-96AB85D531CEQ27003304-6EA9F8C4-424E-4E93-9664-1CA6CD20E604Q27023669-0943FEF8-9D58-4116-829C-FC7964873141Q28550556-886D4E7A-CDCF-4AD2-BDB0-1980BB578F8AQ30249385-A3C287E8-F138-4131-8229-494383A40D2DQ30657649-291194F1-B34C-4236-8E84-F1E8183FD514Q33422744-B96CB7E9-9EF0-43ED-8CE9-DC6414FC50E4Q33555276-FC4251AB-85CE-4E09-B641-4E3974D006A2Q33637053-0F1EFDF2-5753-4FAB-8285-15C1321278A7Q33646171-2159F81A-8DEF-4430-82C5-3C0913FC456FQ33686273-F23832A0-D15E-4DBD-84CD-3422774E8ACFQ33691188-8E12DB5D-F1EB-436A-83C8-A0BC958DD972Q33750154-ADEB5492-B57C-4FCF-BE10-9F9A494848F0Q33822523-A01A508B-066D-403D-A574-13919FAED65FQ33994049-975D5366-2100-40EB-BF95-3F77656DF6D1Q34029286-9823604C-045E-4B7B-8CAE-8E2F0DA02BEEQ34371248-D78B5F76-30D6-4D2F-A571-0D3AE795B090Q34371366-147A4D89-B787-468E-A428-F86ECDBBACA4Q34628575-BBE5CB49-3601-4F10-ABCD-6C932E67EDCBQ34661185-BE7F03B1-575B-4C8E-85DD-FFA4B85DE4C2Q34666150-E23DDD8F-16AC-4A34-BCAB-F847C8273EE5Q35043936-86A92166-409E-447A-B47F-A56F493AEDD0Q35141120-16D54BC7-CDA3-440F-9BA6-645DE3DA20F0Q35495053-8672C986-647C-4F12-91DE-DC8353A73048Q35549876-7D2B072A-1024-42AB-9E10-36B25E7A00CEQ35591482-04EA8214-C6F8-4241-8FB9-C3ADB27AB28FQ35643696-99208283-DD82-4604-8FB2-433001108BCEQ35675548-173D3099-D955-4586-A936-121D0A2704F5Q35678358-FBAC50FD-D8EF-4C5A-8B4E-9870EB54DC3EQ35793032-C63FE262-9970-48F2-8796-AB614FD5E25EQ35813526-B87962AA-A934-4BDD-99BA-BC77547643D4Q36001979-10F5B757-8972-4922-A930-1A2617DB9515Q36048725-A9182FE5-9E82-4577-A35C-F15151F5DB43Q36092896-83F77F40-4D4B-43A5-9475-6790BBE613BEQ36261661-39A0F68D-39B2-4330-A6E1-E89100F4BB54Q36263304-884B0D7F-8EFF-49E4-9574-6CE020B51DFB
P2860
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
description
im September 2012 veröffentlichter wissenschaftlicher Artikel
@de
наукова стаття, опублікована у вересні 2012
@uk
name
Renal cell carcinoma: ESMO Cli ...... nosis, treatment and follow-up
@en
type
label
Renal cell carcinoma: ESMO Cli ...... nosis, treatment and follow-up
@en
prefLabel
Renal cell carcinoma: ESMO Cli ...... nosis, treatment and follow-up
@en
P2093
P2860
P356
P1433
P1476
Renal cell carcinoma: ESMO Cli ...... nosis, treatment and follow-up
@en
P2093
P2860
P304
vii65-vii71
P356
10.1093/ANNONC/MDS227
P433
P577
2012-09-20T00:00:00Z